iifl-logo-icon 1
iifl-logo-icon 1
iifl-logo-icon 1
Home
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

USFDA issues 4 observations to Alembic Pharma's Panelav facility; stock dips ~2%

18 Oct 2022 , 01:56 PM

Alembic Pharmaceuticals Limited informed that the United States Food and Drug Administration (USFDA) inspected the company’s Oncology Injectable Formulation Facility in Panelav between October 4 to October 14, 2022.

USFDA issued a Form 483 with 4 procedural observations.

"Management feels that none of the findings are connected to data integrity and that they can be addressed by the company," said the company in its exchange filing.

The company is now drafting a response to the observations, which will be submitted to the USFDA within the timeframe specified.

The company said that it is committed to maintaining the highest quality standards and compliance at all times.

At around 1.55 PM, Alembic Pharmaceuticals was trading at Rs560.05 down by 1.66% from its previous closing of Rs569.50 on the BSE. The scrip touched intraday high and low of Rs572.85 and Rs557.60 respectively.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Alembic Pharma News
  • Alembic Pharma Stock
  • Alembic Pharma Updates
  • Form 483
  • USFDA Observation
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Most Read News

Indian stock markets end the day in red

Indian stock markets end the day in red

Whatsapp
Facebook
Twitter
LinkedIn
7 May 2024|04:34 PM
Indegene IPO Oversubscribed by 641% so far on Day 2

Indegene IPO Oversubscribed by 641% so far on Day 2

Whatsapp
Facebook
Twitter
LinkedIn
7 May 2024|03:39 PM
SEBI rejects NSE's proposal for extending trading hours

SEBI rejects NSE's proposal for extending trading hours

Whatsapp
Facebook
Twitter
LinkedIn
7 May 2024|04:35 PM
Gland Pharma gets USFDA approval for generic Edaravone injection

Gland Pharma gets USFDA approval for generic Edaravone injection

Whatsapp
Facebook
Twitter
LinkedIn
7 May 2024|04:59 PM
Blackstone in talks to acquire Inspire BKC

Blackstone in talks to acquire Inspire BKC

Whatsapp
Facebook
Twitter
LinkedIn
7 May 2024|05:00 PM
Read More
Marketplus
Derivativesplus
IPOplus
Mutual Fundsplus
Calculatorsplus
Nifty 50plus
Companyplus
Loansplus
Knowledge Centerplus
Newsplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Marketplus
Derivativesplus
IPOplus
Mutual Fundsplus
Calculatorsplus
Nifty 50plus
Companyplus
Loansplus
Knowledge Centerplus
Newsplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

About
IIFL Group
Products & Services
Trading Documentation
Useful Links
ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.